Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — ICR Conference 2021
18 slides from Pyc Therapeutics's conference presentation, Jan 14, 2021
Slide 1: ICR Conference
Life-changing Science For personal use only ICR Conference This announcement has been approved and authorised by the Board of PYC Therapeutics January 2021
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A
Slide 3: PYC is a purpose-focused RNA therapeutics company
PYC is a purpose-focused RNA therapeutics company For personal use only Life-changing Science Building an innovative Unleashing the Creating solutions for biotech in the US to distinctive power of important unmet complement our precision RNA patient need existing Australian therapeutics discovery hu
Slide 4: Key Investment Highlights
Key Investment Highlights For personal use only PYC is an RNA therapeutics company with an initial focus in diseases of the eye ▪ RNA therapeutics have come of age But their ongoing success is impeded by inefficient or toxic delivery inside cells ▪ PYC’s cell-penetrating peptide (CPP) delivery platf
Slide 5: Corporate Snapshot
Corporate Snapshot (ASX: PYC) For personal use only Financial Information (11 January 2021, AUD) Share Price Performance (12 months) ASX website Share price $0.155 Number of shares 3,170M Market Capitalisation $460M Cash $57M Debt Nil Enterprise Value $403M Board of Directors Alan Tribe – Chairman D
Slide 6: Leadership team
Leadership team Executive management For personal use only Sahm Nasseri, Chief Executive Officer US Kaggen Ausma, Chief Business Officer Extensive experience in commercial drug Previous roles in McKinsey & Co across Strategy, development with Merck, incl. product leadership, Commercial, VC and PE, a
Slide 7: World-class RNA therapy design + revolutionary delivery technology
PYC combines World-class RNA therapy design + Revolutionary delivery technology World-class RNA drug design specialists, Delivery technology that enables RNA drugs to For personal use only leveraging Antisense Oligonucleotides reach their target inside the cell ▪ Team led by Chief Scientific Officer
Slide 8: Delivery remains the rate limiting step for RNA drugs
Delivery remains the rate limiting step for RNA drugs PYC’s CPPs have a competitive edge in solving this problem Delivery technology Companies Cargoes Tech dev. stage Technologies core mechanism of action For personal use only Naturally derived cell- PMO Pre-clinical ▪ Utilise library of natural pep
Slide 9: Applying our technology to create life changing treatments, initial focus on eye
PYC is applying our technology to create life changing treatments, with an initial focus on diseases of the eye For personal use only PYC is a multi-asset drug development company Program overview Indication and stage of development Estimated market size Organ Program Target Discovery Lead selection
Slide 10: PYC is in the right place at the right time
PYC is in the right place at the right time “In the long run, oligonucleotides are likely to become a major class of For personal use only therapeutics, on par with small molecules and biologics1” Public RNA focused companies market capitalisation, USD B RNA therapy approvals Drug RNA drug Approved
Slide 11: PYC's drug design team know how to choose the right approach
PYC’s drug design team know how to choose the right approach for the target indication For personal use only Disease state Exons – code for Protein Isoform A protein mRNA Pre-mRNA siRNA’s and ‘Gapmer’ ASOs can alter the exon ASOs can mark mRNA for selection to change the protein. degradation to prev
Slide 12: Many patients with Retinitis Pigmentosa type 11 have no treatment options
There are a large number of patients with Retinitis Pigmentosa type 11 who have no available treatment options For personal use only Retinitis Pigmentosa is a genetic, blinding eye disease ▪ VP-001 will treat Retinitis Pigmentosa Type 11 (RP11) ‒ Severe, progressive blinding eye disease ‒ Onset betw
Slide 13: VP-001 has demonstrated a strong preclinical efficacy signal
VP-001 has already demonstrated a strong preclinical efficacy signal in vivo and in patient derived models For personal use only PYC has demonstrated delivery to the target cells, And shown upregulation of the target protein, PRPF31, in Retinal Pigmented Epithelium (RPE), for 28 days in patient iPSC
Slide 14: Dose dependent response shows no increasing acute toxicity in the mouse
The dose dependant response shows no increasing acute toxicity in the mouse Dose dependant increase in effect … For personal use only … and no increase in toxicity markers Exon-skipping, Day 7 in the mouse eye ddPCR for GFAP expression Gfap expression, Day 7 in the mouse eye in Neural Retina at D7 (
Slide 15: VP-001 can correct important functional deficits associated with RP11
VP-001 has demonstrated the ability to correct important functional deficits associated with RP11 For personal use only These results demonstrate VP-001’s ability to correct the structural deficiency in patient derived retinal cells that is one of the key causes of vision loss in RP11 patients1 1 Bu
Slide 16: VP-001 rescues functional deficits associated with RP11
VP-001 rescues 3 functional deficits associated with RP11 Impact of RP11 For personal use only Structure of the Retina Restoration Healthy RP11 Impact of RP11 with VP-001 ▪ Shorter ‘stunted’ connecting cilium in TBD the photoreceptors ▪ Lower ‘phagocytosis’ of outer segments (lower ability of the RP
Slide 17: CPP-PMO has demonstrated potential outside the eye
PYC’s CPP-PMO has demonstrated potential outside the eye and a clear delivery advantage For personal use only CPP-PMOs demonstrate strong uptake across high value CPP-PMOs show a clear advantage over naked tissues include heart and diaphragm ASOs in delivery to ‘hard to reach’ tissues Exon skipping
Slide 18: Focused on delivering clinical proof-of-concept in lead indication
PYC is focused on delivering clinical proof-of-concept in our lead indication PYC’s potential development pipeline in 2025 Milestones (2021 and 2022 For personal use only highlighted in bold) Organ Program Discovery Pre-clinical IND-enabling Clinical Marketed Ocular VP-001 Retinitis Pigmentosa type